What are the safety risks of modulating this target in humans?

Serious adverse events that surface in Phase I are not always unforeseeable. In many cases, the signal was present in human genetic data — in populations that have been living with altered target activity for their entire lives.

5 Prime Sciences uses this principle to build phenome-wide safety profiles ahead of first-in-human studies. We identify genetic variants that mimic a drug's mode of action on the target — increasing or decreasing protein function — and examine their associations across >57,000 medically relevant outcomes in PRIMEVault™. The result is a systematic account of what happens when that target is perturbed in humans, across diverse genetic backgrounds and over a lifetime of exposure.

Signals are categorised by effect size and significance, with the most relevant adverse events flagged for clinical monitoring. The output informs the design of safety monitoring plans, early trial endpoint selection, and risk mitigation strategies that can be built into first-in-human study protocols before they are required.

This evidence also has a secondary use. In licensing and acquisition discussions, a transparent, data-grounded account of a target's safety liability — produced before clinical exposure — carries more weight than reassurances based on animal data alone.